CHAMPIONS ONCOLOGY, INC. Operating Lease, Expense
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Operating Lease, Expense of $457.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. operating lease, expense for the quarter ending 2026-07-31 was $457.00K, a 0.88% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating lease, expense for the quarter ending 2026-04-30 was $400.00K, a 0.00% change year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating lease, expense for the quarter ending 2026-01-31 was $454.00K, a 0.22% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating lease, expense for the quarter ending 2025-10-31 was $454.00K, a 0.00% change year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating lease, expense for fiscal 2026 was $1.80M, a 0.00% change from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. operating lease, expense for fiscal 2025 was $1.80M, a 0.00% change from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. operating lease, expense for fiscal 2024 was $1.80M, a 5.26% decline from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. operating lease, expense for fiscal 2023 was $1.90M, a 0.00% change from fiscal 2022.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | $457.00K 10-Q · filed 2026-09-11 | $857.00K derived: sum of 2 quarters · filed 2026-09-11 | $1.31M derived: sum of 3 quarters · filed 2026-09-11 | $1.76M derived: sum of 4 quarters · filed 2026-09-11 | |||
| 2026-04-30 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $854.00K derived: sum of 2 quarters · filed 2026-07-27 | $1.31M derived: sum of 3 quarters · filed 2026-07-27 | $1.80M 10-K · filed 2026-07-27 | |||
| 2026-01-31 | $454.00K 10-Q · filed 2026-03-12 | $908.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.40M 10-Q · filed 2026-03-12 | $1.76M derived: sum of 4 quarters · filed 2026-09-11 | |||
| 2025-10-31 | $454.00K 10-Q · filed 2025-12-15 | $907.00K 10-Q · filed 2025-12-15 | $1.31M derived: sum of 3 quarters · filed 2026-09-11 | $1.76M derived: sum of 4 quarters · filed 2026-09-11 | |||
| 2025-07-31 | $453.00K 10-Q · filed 2026-09-11 | $853.00K derived: sum of 2 quarters · filed 2026-09-11 | $1.31M derived: sum of 3 quarters · filed 2026-09-11 | $1.76M derived: sum of 4 quarters · filed 2026-09-11 | |||
| 2025-04-30 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $853.00K derived: sum of 2 quarters · filed 2026-07-27 | $1.31M derived: sum of 3 quarters · filed 2026-07-27 | $1.80M 10-K · filed 2026-07-27 | |||
| 2025-01-31 | $453.00K 10-Q · filed 2026-03-12 | $907.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.40M 10-Q · filed 2026-03-12 | $1.76M derived: sum of 4 quarters · filed 2026-03-12 | |||
| 2024-10-31 | $454.00K 10-Q · filed 2025-12-15 | $907.00K 10-Q · filed 2025-12-15 | $1.31M derived: sum of 3 quarters · filed 2025-12-15 | $1.76M derived: sum of 4 quarters · filed 2025-12-15 | |||
| 2024-07-31 | $453.00K 10-Q · filed 2025-09-15 | $454.00K 10-Q · filed 2024-09-13 | $853.00K derived: sum of 2 quarters · filed 2025-09-15 | $1.31M derived: sum of 3 quarters · filed 2025-09-15 | $1.76M derived: sum of 4 quarters · filed 2025-09-15 | ||
| 2024-04-30 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $854.00K derived: sum of 2 quarters · filed 2025-07-23 | $1.31M derived: sum of 3 quarters · filed 2025-07-23 | $1.80M 10-K · filed 2025-07-23 | |||
| 2024-01-31 | $454.00K 10-Q · filed 2025-03-17 | $908.00K derived: sum of 2 quarters · filed 2025-03-17 | $1.40M 10-Q · filed 2025-03-17 | $1.86M derived: sum of 4 quarters · filed 2025-03-17 | |||
| 2023-10-31 | $454.00K 10-Q · filed 2024-12-16 | $907.00K 10-Q · filed 2024-12-16 | $1.41M derived: sum of 3 quarters · filed 2024-12-16 | $1.88M derived: sum of 4 quarters · filed 2024-12-16 | |||
| 2023-07-31 | $454.00K 10-Q · filed 2024-09-13 | $453.00K 10-Q · filed 2023-09-13 | $954.00K derived: sum of 2 quarters · filed 2024-09-13 | $1.43M derived: sum of 3 quarters · filed 2024-09-13 | $1.90M derived: sum of 4 quarters · filed 2024-09-13 | ||
| 2023-04-30 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-19 | $975.00K derived: sum of 2 quarters · filed 2024-07-19 | $1.44M derived: sum of 3 quarters · filed 2024-07-19 | $1.90M 10-K · filed 2024-07-19 | |||
| 2023-01-31 | $475.00K 10-Q · filed 2024-03-15 | $941.00K derived: sum of 2 quarters · filed 2024-03-15 | $1.40M 10-Q · filed 2024-03-15 | $1.91M derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2022-10-31 | $466.00K 10-Q · filed 2023-12-13 | $934.00K 10-Q · filed 2023-12-13 | $1.43M derived: sum of 3 quarters · filed 2023-12-13 | $1.90M derived: sum of 4 quarters · filed 2023-12-13 | |||
| 2022-07-31 | $467.00K 10-Q · filed 2023-09-13 | $967.00K derived: sum of 2 quarters · filed 2023-09-13 | $1.44M derived: sum of 3 quarters · filed 2023-09-13 | $1.90M derived: sum of 4 quarters · filed 2023-09-13 | |||
| 2022-04-30 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-24 | $969.00K derived: sum of 2 quarters · filed 2023-07-24 | $1.44M derived: sum of 3 quarters · filed 2023-07-24 | $1.90M 10-K · filed 2023-07-24 | |||
| 2022-01-31 | $469.00K 10-Q · filed 2023-03-16 | $936.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.40M 10-Q · filed 2023-03-16 | $1.75M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-10-31 | $467.00K 10-Q · filed 2022-12-13 | $932.00K 10-Q · filed 2022-12-13 | $1.28M derived: sum of 3 quarters · filed 2022-12-13 | $1.59M derived: sum of 4 quarters · filed 2022-12-13 | |||
| 2021-07-31 | $452.00K 10-Q · filed 2022-09-12 | $810.00K derived: sum of 2 quarters · filed 2022-09-12 | $1.12M derived: sum of 3 quarters · filed 2022-09-12 | $1.44M derived: sum of 4 quarters · filed 2022-09-12 | |||
| 2021-04-30 | $358.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-22 | $672.00K derived: sum of 2 quarters · filed 2022-07-22 | $986.00K derived: sum of 3 quarters · filed 2022-07-22 | $1.30M 10-K · filed 2022-07-22 | $1.25M 10-K · filed 2021-07-26 | ||
| 2021-01-31 | $314.00K 10-Q · filed 2022-03-15 | $312.00K 10-Q · filed 2021-03-15 | $628.00K derived: sum of 2 quarters · filed 2022-03-15 | $942.00K 10-Q · filed 2022-03-15 | $941.00K 10-Q · filed 2021-03-15 | $1.17M derived: sum of 4 quarters · filed 2022-03-15 | |
| 2020-10-31 | $314.00K 10-Q · filed 2021-12-13 | $629.00K 10-Q · filed 2021-12-13 | $859.00K derived: sum of 3 quarters · filed 2021-12-13 | $1.10M derived: sum of 4 quarters · filed 2021-12-13 | |||
| 2020-07-31 | $307.00K 10-Q · filed 2021-09-13 | $545.00K derived: sum of 2 quarters · filed 2021-09-13 | $785.00K derived: sum of 3 quarters · filed 2021-09-13 | $1.02M derived: sum of 4 quarters · filed 2021-09-13 | |||
| 2020-04-30 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-26 | $478.00K derived: sum of 2 quarters · filed 2021-07-26 | $717.00K derived: sum of 3 quarters · filed 2021-07-26 | $955.00K 10-K · filed 2021-07-26 | |||
| 2020-01-31 | $240.00K 10-Q · filed 2021-03-15 | $479.00K derived: sum of 2 quarters · filed 2021-03-15 | $717.00K 10-Q · filed 2021-03-15 | ||||
| 2019-10-31 | $239.00K 10-Q · filed 2020-12-14 | $477.00K 10-Q · filed 2020-12-14 | |||||
| 2019-07-31 | $239.00K 10-Q · filed 2020-09-14 | ||||||
| 2018-10-31 | $187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-12-16 | $375.00K 10-Q · filed 2019-12-16 | |||||
| 2018-07-31 | $188.00K 10-Q · filed 2019-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |